Table 3.

GIST VEGF expression and regulation by imatinib

Patient no.GIST genotypeNeoadjuvant imatinib (d)Baseline VEGF statusSurgical VEGF statusProgressed
1WT5++Yes
2PDGFR Asp583 Glu del 2143-21547No
3Kit exon 11 del 555 and 556 (V555_Q556del)3No
4Kit exon 11 del 560 (V560del)7No
5Kit exon 9 6 bp duplication 507 and 503 (A502_Y503dup)3++Yes
6Kit exon 11 12 bp duplication of codons 577 to 58 (P577_H580dup)3+No
7KIT exon 11 48 bp insertion and duplication of 16 amino acids3+Yes
8Kit exon 11 36 bp deletion codons 559 to 570 (V559_Y570del) and a K55BN change at the junctional site7Yes
9Kit exon 11 point mutation (TGG to CGG) Trp-Arg (W557R)5No
10Kit exon 11 6 bp deletion codons 557 to 558 (W557_K558del)5No
11Kit exon 11 6 bp deletion codons 558 to 559 (K558_K559del)7No
12KIT exon 11 15 bp deletion 554 to 558 (E554_K558del)3No
Total positive (%)4 (33)2 (16)4 (33)
  • NOTE: Genotype, pre-imatinib and post-imatinib VEGF protein expression by immunohistochemistry, and progression status from patients on MDACC ID03-0023.

    Abbreviations: Baseline, VEGF expression in pre-imatinib core needle biopsy of GIST; surgical, VEGF expression in post-imatinib surgical specimen of GIST; +, positive for VEGF expression; −, negative for VEGF expression; yes, patient did progress after resection of tumor; no, patient has not progressed after resection of tumor.